A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
第3相
実施中（募集終了）
NCT05104866
| 対象疾患 | Breast Cancer |
|---|
| 相 | 第3相 |
|---|
| スポンサー | AstraZeneca |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 732 名 |
|---|
| 介入（薬剤） | Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine |
|---|
| 開始日 | 2021年10月18日 |
|---|
| 完了日 | 2024年7月24日 |
|---|
| 結果公開日 | 2026年2月4日 |
|---|
概要
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.
Progression-Free Survival
On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months · Months
| Dato-DXd | 6.9 Months |
|---|
| Investigator's Choice of Chemotherapy (ICC) | 4.9 Months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.63 (95% CI 0.49–0.80) |
|---|
Overall Survival
From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months. · Months
| Dato-DXd | 18.6 Months |
|---|
| Investigator's Choice of Chemotherapy (ICC) | 18.3 Months |
|---|
| p-value | 0.9445 |
|---|
| Hazard Ratio (HR) | 1.01 (95% CI 0.83–1.23) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。